![Kevin T. Sprott](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kevin T. Sprott
Fundador en Stablix, Inc. .
Cargos activos de Kevin T. Sprott
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Stablix, Inc.
![]() Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | Director/Miembro de la Junta | - | - |
Director de Operaciones | 26/05/2022 | - | |
Fundador | - | - | |
Corporate Officer/Principal | 01/03/2021 | 26/05/2022 |
Historial de carrera de Kevin T. Sprott
Antiguos cargos conocidos de Kevin T. Sprott.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Millennium Pharmaceuticals, Inc.
![]() Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
VERASTEM, INC. | Corporate Officer/Principal | - | - |
IRONWOOD PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
SYROS PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
Formación de Kevin T. Sprott.
University of Kansas | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 7 |
Operativa
Corporate Officer/Principal | 5 |
Doctorate Degree | 1 |
Director/Board Member | 1 |
Sectorial
Health Technology | 5 |
Consumer Services | 2 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
SYROS PHARMACEUTICALS, INC. | Health Technology |
VERASTEM, INC. | Health Technology |
IRONWOOD PHARMACEUTICALS, INC. | Health Technology |
Empresas privadas | 2 |
---|---|
Millennium Pharmaceuticals, Inc.
![]() Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Stablix, Inc.
![]() Stablix, Inc. Miscellaneous Commercial ServicesCommercial Services Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022. | Commercial Services |
- Bolsa de valores
- Insiders
- Kevin T. Sprott
- Experiencia